A nonprofit health advocacy group wants Bayer to swallow yet another bitter legal pill over its marketing techniques — this one involving its Men’s One A Day multivitamin.

The Washington, D.C.-based Center for Science in the Public Interest (CSPI) is suing the German drug giant for allegedly claiming falsely that selenium in the men’s multivitamin might reduce the risk of prostate cancer.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]